Myokine myostatin is a novel predictor of one-year radiographic progression in patients with rheumatoid arthritis: A prospective cohort study

Jian‐Zi Lin, Jian‐Da Ma, Lijuan Yang, Yao-Wei Zou, Xuepei Zhang, Jie Pan, Qianhua Li, Honggui Li, Zehong Yang, Tao Wu, Qian Zhang, Ying‐Qian Mo, Lie DaiFrontiers in Immunology 2022 · DOI

TL;DR

This study identifies myostatin, a protein produced by muscles, as a novel predictor of joint damage progression in rheumatoid arthritis (RA) patients over one year. Notably, high levels of myostatin combined with muscle weakness (myopenia) show a synergistic effect, significantly increasing the risk of aggravated joint destruction.

What Problem Does This Paper Address?

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and progressive destruction of joints. Beyond joint damage, RA also leads to systemic issues, including a significant prevalence of reduced skeletal muscle mass, termed myopenia. While previous research has linked myopenia to worse joint outcomes in RA, the role of myokines – signaling molecules secreted by muscles – in this process has been less clear. Myostatin, a myokine known to negatively regulate muscle mass and potentially influence bone health, has not been thoroughly investigated as a predictor of RA disease progression. This paper aims to fill this gap by exploring the relationship between serum myostatin levels, disease characteristics, and the progression of joint destruction in RA patients over a one-year period.

Methods

The researchers conducted a prospective cohort study involving consecutive RA patients. They collected baseline serum samples to measure myostatin levels using enzyme-linked immunosorbent assay (ELISA). Clinical data, including disease activity and physical function, were gathered at baseline and over a one-year follow-up. Skeletal muscle mass was assessed using bioelectric impedance analysis to determine appendicular skeletal muscle mass index (ASMI). Radiographic progression, the primary outcome, was defined by changes in the modified total Sharp/van der Heijde score (mTSS) over 12 months. Statistical analyses included comparisons between groups, correlation analyses, and logistic regression models to identify risk factors and interactions. They specifically investigated the synergistic effect of high myostatin and myopenia on radiographic progression using additive and multiplicative scales.

Datasets

The study utilized data from a real-world prospective cohort of 344 RA patients and 118 healthy control subjects. The RA patient cohort was recruited between July 2015 and February 2019. Healthy controls were recruited from May 2019 to April 2020. No new datasets were introduced; the study relied on existing patient data collected over time.

Key Insights and Ideas

  • Myostatin as a Double-Edged Sword: While myostatin is known to regulate muscle mass, its role in RA appears complex, potentially influenced by both muscle tissue and systemic inflammation.
  • Synergistic Risk: The combination of high myostatin and myopenia doesn't just add risk; it amplifies it. This synergistic interaction is a crucial finding, suggesting a combined therapeutic target.
  • Myostatin's Impact on Bone: The study provides strong evidence that myostatin, beyond its muscle effects, directly contributes to bone destruction in RA, acting as a potential anti-osteogenic factor.
  • Myokines and Systemic Inflammation: The findings suggest a link between myostatin and RA disease activity, hinting at a broader role for myokines in the systemic inflammatory processes of RA.

Key Results

  • RA patients exhibited significantly higher serum myostatin levels and lower appendicular skeletal muscle mass index (ASMI) compared to healthy controls.
  • High baseline serum myostatin levels were associated with a higher rate of radiographic progression over one year (45.3% vs. 18.6% in low myostatin group).
  • Myopenia was also identified as a risk factor for radiographic progression.
  • Patients with both high myostatin and myopenia showed the highest rate of radiographic progression (67.2%).
  • Multivariate logistic regression confirmed that high serum myostatin (AOR=3.451) and myopenia (AOR=2.387) were independent risk factors for one-year radiographic progression.
  • A significant synergistic interaction effect was observed between high myostatin and myopenia on one-year radiographic progression, with the additive interaction accounting for 66.3% of the risk.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-Center Study: The study was conducted at a single center, limiting generalizability. They recommend multicenter studies for broader validation.
  • Proportion of Treatment-Naïve Patients: The cohort included a relatively small proportion of treatment-naïve patients. While myostatin remained a risk factor even after adjusting for confounders, future studies should recruit more treatment-naïve patients or standardize treatment regimens to mitigate potential confounding effects.

Future work should focus on further exploring the underlying mechanisms of myostatin's role in RA, particularly its interaction with inflammation and bone metabolism. The development of myostatin inhibitors is highlighted as a promising therapeutic strategy for managing both myopenia and joint destruction in RA.

Summary updated

Abstract

Myostatin is a novel predictor of aggravated joint destruction in RA patients which has synergistic interaction with myopenia for predicting value.
BibTeX
@inproceedings{lin2022myokine,
  author = {Jian‐Zi Lin and Jian‐Da Ma and Lijuan Yang and Yao-Wei Zou and Xuepei Zhang and Jie Pan and Qianhua Li and Honggui Li and Zehong Yang and Tao Wu and Qian Zhang and Ying‐Qian Mo and Lie Dai},
  title = {{Myokine myostatin is a novel predictor of one-year radiographic progression in patients with rheumatoid arthritis: A prospective cohort study}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.1005161},
}
Figure